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Abstract
Background Recent studies report an increased risk of non-melanoma skin cancer (NMSC) in immunosuppressed
patients with inflammatory bowel disease (IBD). Concurrently, paediatric IBD incidence is rising, with more patients now
exposed to immunomodulators from a younger age.
Objectives To investigate NMSC incidence and to examine the risk associated with immunomodulators in the devel-
opment of NMSC in patients with IBD.
Methods This was a retrospective single-centre cohort study. Patients with IBD attending a tertiary adult hospital from
1994 to 2013 were included. Skin cancer incidence was compared with population data from the National Cancer Registry of
Ireland (NCRI) to calculate standardized incidence ratio (SIR). Logistic regression was utilized for risk factor analysis.
Results Two thousand and fifty-three patients with IBD were studied. The SIR for NMSC in patients with IBD taking
immunomodulators overall was 1.8 (95% CI: 1.0–2.7) with age-specific rates significantly elevated across certain age
categories. Exposure to thiopurines (OR: 5.26, 95% CI: 2.15–12.93, P < 0.001) and in particular thiopurines and/or
tumour necrosis factor alpha (TNF-a) inhibitors (OR: 6.45, 95% CI: 2.69–15.95, P < 0.001) was significantly associated
with NMSC. The majority (82%) of those exposed to a TNF-a inhibitor also had thiopurine exposure.
Conclusions Compliance with skin cancer preventative measures should be highlighted to all patients with IBD. There
should be a low threshold for dermatology referral for immunosuppressed patients, particularly those with a history of
exposure to dual immunomodulators from a young age.
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Introduction
Non-melanoma skin cancer (NMSC) is the commonest malignancy
in white populations, and its incidence is increasing worldwide.1
Reporting practices vary internationally; however within Europe,
Ireland has the highest documented incidence of NMSC (149/
100 000 person-years) amounting to over 6800 cases annually.2
Inflammatory bowel disease affects an estimated 20 000 peo-
ple in Ireland.3 Thiopurines and tumour necrosis factor alpha
inhibitors are the two most commonly prescribed medication
classes after aminosalicylates. Earlier initiation and increasing
use of these immunosuppressive agents for prolonged periods
has raised concerns regarding the long-term potential associa-
tion with malignancy. This is of particular relevance given the
rising incidence of IBD described internationally amongst chil-
dren <16 years old.4 In Ireland, these rates have more than
doubled from 2.5/100 000/year in 2001 to 5.6 in 2010.5
It is well recognized that the risk of NMSC is increased in
immunosuppressed patients.6–8 This is most evident amongst
transplant recipients, in whom squamous cell carcinomas
(SCCs) occur 65–250 times as frequently as in the general
© 2017 European Academy of Dermatology and VenereologyJEADV 2017, 31, 978–985
DOI: 10.1111/jdv.14105 JEADV
population and basal cell carcinomas (BCCs) are increased by a
factor of 10. The risk of melanoma is also increased but to a les-
ser degree (up to eightfold).9,10 Recent epidemiological studies
support the theory that patients with IBD are also more likely to
develop NMSC.11–15 Although the incidence of skin cancers in
IBD is increased by immunomodulators, the absolute numbers,
when compared to transplant recipients, are low.16,17 The higher
incidence of NMSC in IBD has been attributed to both inherent
immune dysregulation and exposure to immunosuppressive
agents, particularly thiopurines.15,18 Ongoing and past exposure
to thiopurines appears to significantly increase the risk of NMSC
in patients with IBD even before the age of 50 years.15
Tumour necrosis factor alpha inhibitors in IBD are also associ-
ated with NMSC,19,20 but there are less conclusive data in this area.
Strong evidence now supports the use of combined infliximab and
azathioprine in moderate-to-severe CD21 and UC,22 potentially
placing this cohort at greater risk due to dual immunosuppression.
Objectives
The aims of this study were to compare the incidence of NMSC
in both immunosuppressed and non-immunosuppressed
patients with IBD, with the general population, and to investi-
gate the risk associated with immunomodulators in the develop-
ment of NMSC in patients with IBD.
Materials and methods
Participants and eligibility criteria
This was a retrospective single-centre cohort study. Approval
was obtained from the hospital ethics committee. Patients were
identified from a computerized IBD database of patients attend-
ing a tertiary referral adult hospital. Recorded patient
demographics included date of birth, sex, smoking status, IBD
subtype, date of IBD diagnosis and immunosuppressive medica-
tion exposure. The database did not specify the dose or duration
of treatment with each immunomodulator. Diagnosis of IBD
was confirmed by standard clinical, radiologic, endoscopic and
histologic criteria.23
The IBD database was cross-referenced with the National
Cancer Registry of Ireland (NCRI) records of NMSC. Registra-
tion has covered the population of Ireland since 1994 and the
NCRI aims for complete ascertainment of all cases of NMSC.24
Ninety-five per cent of BCC and 98% of SCC are histologically
verified.2 Patients were matched to the NCRI database in mid-
August 2013. All skin cancers diagnosed from January 1994 to
mid-2013 (and registered on the database) were included.
NMSC was defined as any invasive skin cancer (ICD 10; code
C44.0–C44.9) excluding melanoma (C43.0–C43.9). BCCs were
defined as skin cancers with morphology M-8090–M-8110, and
SCCs as skin cancers with morphology M-8070–M-8084,
behaviour code 3 (invasive).2
Exclusion criteria
Patients were excluded if their IBD diagnosis preceded 1994, as
skin cancer incidence data were not available prior to this date,
if they were known solid organ transplant recipients or greater
than 85 years old. Patients with an incomplete dataset were also
excluded from the final analysis. Incident NMSCs only were
included. Based on these criteria, 2053 of 3183 patients in total
were eligible (Fig. 1).
Statistical methods
The first of each NMSC subtype per patient only was recorded
in our results. The patients’ study entry date corresponded with
their date of IBD diagnosis. The study end date was the last date
matched to the NCRI database (19 August 2013).
Standardized incidence ratios (SIRs) were calculated by divid-
ing the observed numbers of cancers in the IBD cohort by the
expected number. Expected cases were calculated from the pro-
duct of the average national age and gender-specific incidence
rates for 1994–2013 and the number of person-years at risk. SIRs
for SCC and BCC were combined due to the low individual
incidence figures in our cohort.
Logistic regression analysis was used to determine factors
affecting the probability of IBD patients developing NMSC using
the R function generalized linear model.25 The explanatory vari-
ables specified were age as of 19 August 2013, gender, IBD sub-
type and exposure to immunomodulators including thiopurines
(azathioprine and 6 mercaptopurine) and TNF-a inhibitors
(adalimumab, infliximab and certolizumab pegol). Time since
IBD diagnosis was included as an offset in the model to account
for varying disease duration. Significance was confirmed using
both P-value analysis and model selection via stepwise Akaike
Information Criterion (AIC) model selection.25 Statistical signif-
icance was assumed for P-values <0.05. The models examined
the association of immunomodulator exposure with NMSC. The
first model included thiopurines (azathioprine and 6-mercapto-
purine), and the second model included patients exposed to
thiopurines and TNF-a inhibitors. Only 3% (n = 41) of
immunosuppressed patients had been exposed to TNF-a inhibi-
tors alone, and therefore, further analysis of this subgroup was
not undertaken.
More patients were exposed to azathioprine (n = 850, 41%)
compared to any other immunosuppressive drug in this study.
Further analysis of the SIR for azathioprine was subsequently
calculated specifically by age and gender using a generalized lin-
ear model (Appendix 1). Due to the low overall incidence of
NMSC in the cohort, even small fluctuations in observed skin
cancers in age groups of close proximity would have resulted in
erratic-appearing SIRs. Poisson regression model analysis was
therefore used, which borrows strength between categories and
is superior to treating categories separately.25 The dependent
variable for the Poisson regression was observed counts of skin
cancer. Explanatory variables were age, gender and azathioprine
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exposure. The natural log (ln) of patient years was used as an
offset so that the model reflected the rate of observed skin cancer
relative to patient years. Expected values were based on the
NCRI data, with the relevant incidence rate of each age category
applied to the number of patient years, to provide an expected
incidence for each age category. The SIR rate was calculated as
the fitted values from the Poisson regression model divided by
these expected values.
Results
Demographics
There were 3183 patients in the IBD database. Following the
application of all exclusion criteria, 2053 were included in
the final analysis (Fig. 1). The study population characteristics
are outlined in Table 1. Eight hundred and forty patients
(41%) had Crohn’s disease (CD) and 1213 (59%) had ulcera-
tive colitis (UC). Median age at IBD diagnosis was 31.1 years
(range 2.4–80.6 years) and median duration of illness per
patient was 9.8 years (range 1 month–19.6 years) with over
20 000 person-years of follow-up. There were 1179 (57%)
patients who had been exposed to immunosuppressive medi-
cation and 874 (43%) who had not. Of the immunosup-
pressed cohort, 92% had been exposed to a thiopurine and
44% to a TNF-a inhibitor. Eighty-two per cent of patients
on TNF-a inhibitors had also been exposed to thiopurines.
Patients with IBD who were immunosuppressed were more
likely to be younger (P < 0.001) and to have a diagnosis of
CD rather than UC (P < 0.001).
Skin cancer
There were 34 incident cases of NMSC (1.7% of total cohort), 17
in both the immunosuppressed and non-immunosuppressed
groups (Table 2). Nine patients had an SCC, 25 had a BCC and
two patients had both an SCC and BCC. All immunosuppressed
patients with NMSC had thiopurine (specifically azathioprine)
exposure. Six patients (35%) had also been exposed to TNF-a
inhibitor. The mean age at NMSC diagnosis was 54.1 years (SD
12.7 years), and the mean IBD duration at time of diagnosis was
7.5 years (SD 5.4 years).
Standardized incidence ratios
The SIR for NMSC in all patients with IBD (i) both immuno-
suppressed and non-immunosuppressed, (ii) immunosup-
pressed only, (iii) non-immunosuppressed only and (iv)
exposed to thiopurines only is outlined in Table 3. These results
demonstrate that NMSC is more common in all of these groups
than in the general population. This increased risk of NMSC
approaches statistical significance in the entire group of patients
with IBD (SIR 1.3, 95% CI: 0.9–1.8).
The graphs in Figs 2 and 3 show the age-related variation in
the SIRs for NMSC amongst males and females exposed to
Total database = 3183
IBD diagnosed pre-1994 (-1016)
Skin  cancer 
pre-IBD diagnosis (-4)
Incomplete data (-15)
Immunosuppressed = 1198
Skin  cancer 
pre-IBD diagnosis (-2)
Incomplete data (-36)
Non-immunosuppressed = 912
Eligible patients = 2053
(F = 1003; M = 1050; CD = 840; UC = 1213)
Immunosuppressed = 1179
NMSC : 17 cases, 17 patients
SCC : 3
F = 1; M = 2
BCC : 14
F = 5; M = 9
SCC : 6
F = 4; M = 2
BCC : 11
F = 8; M = 3
NMSC : 17 cases, 15 patients
Non-immunosuppressed = 874
Age >85 (-55)
Subtotal = 2110
Transplant recipients (-2)
Figure 1 Patients recruited to study. BCC, basal cell carcinoma; CD, Crohn’s disease; F, female; IBD, inflammatory bowel disease; M,
male; NMSC, non-melanoma skin cancer; UC, ulcerative colitis; SCC, squamous cell carcinoma.
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azathioprine. This exposure appears to have greatest effect from
age 30–50 and also in the over 70s; however, it should also be
noted that the confidence intervals are wide. The SIR appears
higher in males as compared to females, particularly up to age
45–50, but again wide confidence intervals are present.
Logistic regression analysis
Thiopurine exposure (Table 4, i) was significantly associated
with a risk of developing NMSC and had an odds ratio of
5.26 (95% CI: 2.15–12.93, P < 0.001). Patients exposed to
both thiopurines and TNF-a inhibitors (Table 4, ii), however,
had the highest odds ratio of 6.45 (95% CI: 2.69–15.95,
P < 0.001). Notably, 82% of patients who had exposure to
TNF-a inhibitors also had thiopurine exposure. Only 41
patients had been exposed to TNF-a inhibitors alone, and
therefore, no significant association with NMSC could be
determined. Ageing was a significant risk factor across all cat-
egories of immunosuppression. Gender, smoking history and
Table 1 Patient characteristics and drug exposure
All patients
(n = 2053)
Immunosuppressed
patients (n = 1179)
Non-immunosuppressed
(n = 874)
P-value
Gender
Male 1050 (51%) 619 (53%) 431 (49%) 0.15
Female 1003 (49%) 560 (47%) 443 (51%)
IBD subtype, n (%)
Crohn’s 840 (41%) 577 (49%) 263 (30%) <0.001
Ulcerative colitis 1213 (59%) 602 (51%) 611 (70%)
Median age at diagnosis with IBD (range) 31.1 years
(2.4–80.6 years)
29.1 years
(6.5–77.6 years)
33.7 years
(2.4–80.6 years)
<0.001
Median duration of illness (range) 9.8 years
(1 month–19.6 years)
9.7 years
(1 month–19.6 years)
10.2 years
(1 month–19.6 years)
0.36
Median age at end of study (range) 41.4 years
(16.5–84.5 years)
39.0 years
(17.0–84.4 years)
44.5 years
(16.5–84.5 years)
<0.001
Drug exposure
Thiopurine, n (%) 1084 (53%) 1084 (92%) 0 (0%)
AZA total, n (%) 850 (41%) 850 (72%) 0 (0%)
AZA only, n (%) 748 (36%) 748 (63%) 0 (0%)
6MP total, n (%) 149 (7%) 149 (13%) 0 (0%)
6MP only, n (%) 47 (2%) 47 (3%) 0 (0%)
AZA & 6MP, n (%) 102 (5%) 102 (9%) 0 (0%)
Thiopurine unspecified, n (%) 187 (9%) 187 (16%) 0 (0%)
TNF-a inhibitors total, n (%) 513 (25%) 513 (44%) 0 (0%)
TNF-a inhibitors only, n (%) 41 (2%) 41 (3%) 0 (0%)
Both thiopurine and TNF-a inhibitors, n (%) 421 (21%) 421 (36%) 0 (%)
Both azathioprine and TNF-a inhibitors, n (%) 385 (19%) 385 (33%) 0 (0%)
Smoker at diagnosis
No 1037 (50%) 617 (52%) 420 (48%)
Yes 387 (19%) 238 (20%) 149 (17%)
Ex-smoker 326 (16%) 185 (16%) 141 (16%)
Unknown 303 (15%) 139 (12%) 164 (19%)
AZA, azathioprine; IBD, inflammatory bowel disease; 6 MP, 6 mercaptopurine; n, number; TNF-a inhibitors, tumour necrosis factor alpha inhibitors.
Table 2 Non-melanoma skin cancer distribution
All patients
(n = 2053)
Immuno
suppressed
patients
(n = 1179)
Non-
immuno
suppressed
(n = 874)
Exposed to
thiopurine
(n = 1084)
Not exposed to
thiopurine
(n = 969)
TNF exp
(n = 513)
SCC only 7 (0.3%) 3 (0.3%) 4 (0.5%) 3 (0.3%) 4 (0.4%) 2 (0.4%)
BCC only 25 (1.2%) 14 (1.2%) 11 (1.3%) 14 (1.3%) 11 (1.1%) 4 (0.8%)
SCC & BCC 2 (0.1%) 0 2 (0.2%) 0 2 (0.2%) 0
Total NMSC 34 (1.7%) 17 (1.4%) 17 (1.9%) 17 (1.6%) 17 (1.8%) 6 (1.2%)
BCC, basal cell carcinoma; n, number; NMSC, non-melanoma skin cancer; SCC, squamous cell carcinoma.
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IBD subtypes were not associated with NMSC risk in any
models.
Discussion
This retrospective single-centre cohort study of patients with
IBD examines NMSC incidence spanning almost 20 years
from 1994 until mid-2013. The incidence of NMSC was
1.7% in the total cohort (n = 34/2053), 1.4% in immuno-
suppressed patients (n = 17/1179) and 1.9% in non-
immunosuppressed patients (n = 17/874). The ratio of BCC
to SCC (approaching 3:1) is similar to the general popula-
tion;2 however, it must be interpreted with caution given
the low case numbers.
Exposure to UV radiation is recognized as the primary cause
of NMSC,26 correlating with higher NMSC incidence associated
with decreasing latitudes, sun seeking behaviour and indoor
tanning. Ultraviolet A (UVA) radiation and azathioprine act as
synergistic mutagens27 due to the incorporation of 6 thioguanine
(6 TG), the active metabolite of thiopurines, into DNA. Azathio-
prine is generally the first-line thiopurine used in Europe and is
classified as a carcinogen by the International Agency for
Research on Cancer.28 Even in temperate climates, patients are
at risk, given that UVA accounts for 95% of ambient sunlight, is
present year-round, can penetrate glass and to basal layer stem
cells where carcinogenic changes may persist post-treatment.27
Unlike azathioprine, TNF-a inhibitors are not photosensitizers,
but it is hypothesized that overexposure to insulin-like growth
factor 1 (IGF-1), secondary to TNF-a inhibition, may be linked
to malignancy.20,29,30
Advancing age was also identified as a significant risk factor in
the development of NMSC in this study (P < 0.001), which may
account for the higher overall skin cancer incidence in the non-
Table 3 Standardized incidence ratios for non-melanoma skin cancer in comparison with the general population
All IBD Non-
immunosuppressed
All
immunosuppressed
Thiopurines
SIR 1.3 1.07 1.76 1.8
95% Confidence interval 0.9–1.8 0.6–1.6 1.0–2.7 1.0–2.8
IBD, inflammatory bowel disease; SIR, standardized incidence ratio.
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Figure 2 Standardized incidence ratio of non-melanoma skin
cancer in male patients with inflammatory bowel disease in relation
to azathioprine exposure (dotted lines represent confidence inter-
vals). AZA, azathioprine; non-AZA, not exposed to azathioprine or
other immunosuppression.
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Figure 3 Standardized incidence ratio of non-melanoma skin
cancer in female patients with inflammatory bowel disease in rela-
tion to azathioprine exposure (dotted lines represent confidence
intervals). AZA, azathioprine; non-AZA, not exposed to azathio-
prine or other immunosuppression.
Table 4 Final logistic regression analysis for (i) model including
thiopurine exposure and (ii) model including exposure to thiopurine
and/or tumour necrosis factor alpha inhibitors
Variables Odds
ratio
95% CI P-value
(i) Thiopurine exposure only
(not TNF-a inhibitors)
5.26 (2.15, 12.93) <0.001
Age 1.13 (1.1, 1.18) <0.001
(ii) Thiopurine and/or TNF-a
inhibitor
6.45 (2.69, 15.95) <0.001
Age 1.14 (1.1, 1.18) <0.001
(i) Logistic regression analysis for model including thiopurine exposure, age,
gender, smoking status and type of inflammatory bowel disease. Significant
variables were thiopurine exposure and age as shown with P-values and
odds ratios including 95% confidence interval. TNF-a = tumour necrosis
factor alpha.
(ii) Logistic regression analysis for model including exposure to a thiopurine
and/or tumour necrosis factor alpha (TNF-a) inhibitors, age, gender, smoking
status and type of inflammatory bowel disease. Significant variables were
thiopurine exposure and age as shown with P-values and odds ratios
(including 95% confidence interval).
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immunosuppressed cohort. Ageing is associated with decreasing
capacity to repair DNA, falling by 0.61% annually from age 20.31
Patients with IBD and a history of exposure to immunosuppres-
sion were significantly younger (median age at end of study:
39 years; range 17–44.5 years) than non-immunosuppressed
patients (median age: 44.5 years; range 16.5–84.5 years,
P < 0.001). National skin cancer incidence statistics corroborate
these findings and show an age-related increase in melanoma
and NMSC, particularly SCC, over age 65.2
It is, however, important to note that younger IBD patients
on immunomodulators had relatively higher rates of NMSC,
when compared to their peers in the general population (SIR:
1.76; CI = 1–2.7), whereas marginally higher SIR in the non-
immunosuppressed cohort compared to age-matched counter-
parts was not significant (SIR: 1.07; CI = 0.6–1.6). The SIR for
NMSC was also noted to be higher in males exposed to azathio-
prine compared to females of similar age; however given the
wide confidence intervals, this data must be interpreted
conservatively. Additional risk factors, e.g. greater UV exposure
or perhaps lesser compliance with photoprotection, may be of
more importance in this group.
Patients with IBD and a history of exposure to thiopurines
and/or TNF-a inhibitors had the highest odds of developing
NMSC (OR: 6.45; 95% CI: 2.69–15.95, P < 0.001). Notably, the
majority (82%) of those exposed to TNF-a inhibitors also had
thiopurine exposure. Dual immunosuppressive regimens con-
sisting of azathioprine and infliximab are superior to either
agent alone in moderate-to-severe Crohn’s and UC,21,22 but cor-
respondingly also carry the greatest risk of developing NMSC
according to our results. This supports intuitive reasoning that
more potent immunosuppression carries the greatest risk. These
findings correlate with outcomes from Mc Kenna et al.20 who
demonstrated that TNF-a inhibitor monotherapy and combina-
tion treatment with a thiopurine were both significantly associ-
ated with NMSC (P < 0.001). Only 3% (n = 41/1179) of
immunosuppressed patients in our cohort had exposure to
TNF-a inhibitors without thiopurines, and therefore, no signifi-
cant association due to TNF-a inhibition alone could be
determined.
From our results, thiopurines (azathioprine and/or 6 mercap-
topurine) had an OR of 5.26 (95% CI: 2.15–12.93, P < 0.001).
Accordingly, the CESAME (Cancers Et Surrisque Associe aux
Maladies inflammatoires intestinales En France) observational
cohort showed that ongoing thiopurine exposure (HR 5.9; 95%
CI: 2.1–16.4 P < 0.0006) and past exposure (HR 3.9; 95% CI:
1.3–2.1, P < 0.02) significantly increased NMSC risk in patients
with IBD, even before the age of 50.15
Overall, our results are of concern, given the rising number of
IBD diagnoses under the age of 18,6 the earlier introduction of
immunomodulatory therapy and the increasing use of combina-
tion treatments.32 Due to the prevalence of NMSC, even
low-level escalation can lead to a sizeable impact on caseload,
morbidity and economic burden. Currently, NMSC costs
approximately €17 million annually in Ireland2 and is projected
to reach £180 million in the UK by 2020.33
Consensus opinion, however, is that immunomodulatory
treatment should not be limited by these risks.34 Other
studies35,36 have failed to find conclusive associations between
specific immunomodulator classes and NMSC in IBD, and
therefore, a meta-analysis is warranted.
Long-term azathioprine remains the first-line immunomodu-
latory treatment for patients with IBD, given its efficacy and
relapse rates of 65–75% off-therapy.37 Mycophenolate mofetil,
which has a more favourable risk profile as regards cutaneous
malignancies, is less effective with variable tolerance in IBD38
and is not currently recommended.38,39 Age, previous skin
malignancy, significant UV exposure and reduced thiomethyl-
purine transferase (TPMT) activity should be taken into
account,40 and clinical IBD guidelines39 that strongly advocate
photoprotection should be reinforced. A US study recently con-
cluded that annual screening of all patients with Crohn’s disease
was the most successful and cost-effective strategy for early
detection of NMSC,41 but within the constraints of a public
health service, regular skin screening is not always feasible.
Strengths
This is the first study examining NMSC risk in patients with IBD
in an Irish population, which is situated in a relatively homoge-
nous area as regards latitude, sun exposure and skin phototype.
Irish patients are predominantly fair-skinned42 with 94%43 self-
reporting white skin type. The NCRI provides robust data on all
NMSC in Ireland, giving true incidence figures for BCC and
SCC. This contrasts with some international registries, which do
not record certain subtypes.1 Although the study population was
relatively small (n = 2053), the retrospective review period
reviewed was almost 20 years, amounting to over 20 000 patient
years of data.
Limitations
The limitations include the small sample size and low incidence
rate, although our NMSC case numbers are comparable to previ-
ous studies.15,44 The analysis was based on a hospital database,
which may over-represent severe IBD. Only 30% of patients with
IBD attend for regular hospital follow-up,5 introducing both
selection and ascertainment bias. These patients generally have
serious underlying disease requiring immunosuppression, more
frequent follow-up and may have higher dermatology referral
rates.
Duration of exposure to particular immunosuppressive treat-
ments can be challenging to ascertain and was not recorded in
this database, similar to previous studies.37,44 We did not have
data on prior UV exposure, which may have revealed age- or
gender-related variation, but patients were resident within a lim-
ited geographical area. Analysis of the dose-dependent effect of
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thiopurines on NMSC, adjusting for TPMT activity, was not
possible, as TPMT levels were not recorded in the IBD cohort.
This would be an interesting area to pursue in future studies
investigating patient risk stratification.
Conclusions
This retrospective cohort study shows a small but significantly
increased incidence of NMSC in immunosuppressed patients
with IBD, as compared to the general population. It identifies
ageing, exposure to thiopurines alone and in combination with
TNF-a inhibitors as risk factors in the development of NMSC
within this cohort. The relatively high SIRs for NMSC amongst
younger immunosuppressed patients are particularly concerning
given the rising incidence of IBD in the paediatric and young
adult population. This trend, combined with the increasing use
of dual immunomodulatory therapy for sustained periods, is
likely to contribute to higher rates of NMSC amongst this cohort
in future. Nevertheless, immunosuppressive treatment remains a
vital component of disease management in IBD, and therefore,
greater emphasis must be placed on primary preventive mea-
sures, as outlined in clinical guidelines.39 In the setting of limited
healthcare resources, our results support targeted dermatology
referrals for patients with IBD, particularly those exposed to dual
immunomodulatory therapy from an early age.
Acknowledgement
The authors wish to acknowledge Dr Karen Eustace, who
assisted with the study proposal and ethics submission.
References
1 Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of world-
wide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166:
1069–1080.
2 Deady S, Sharp L, Comber H. Increasing skin cancer incidence in young,
affluent, urban populations: a challenge for prevention. Br J Dermatol
2014; 171: 324–331.
3 Irish Society for Colitis and Crohn’s Disease. 2014. http://www.iscc.ie/
facts.
4 Benchimol EI, Fortinsky KJ, Godzdyra P et al. Epidemiology of paediatric
inflammatory bowel disease: a systematic review of international trends.
Inflamm Bowel Dis 2010; 17: 423–439.
5 Hope B, Shahdadpuri R, Dunne C et al. Rapid rise in incidence of Irish
paediatric inflammatory bowel disease. Arch Dis Child 2012; 97:
590–594.
6 Engels EA, Pfeiffer RM, Goedert JJ et al. Trends in cancer risk among
people with AIDS in the United States 1980–2002. AIDS 2006; 20: 1645–
1654.
7 Brewer J, Haberman TM, Shanafelt TD. Lymphoma-associated skin can-
cer: incidence, natural history, and clinical management. Int J Dermatol
2014; 53: 267–274.
8 Moloney FJ, Comber H, O’Lorcain P, O’Kelly P, Conlon PJ, Murphy
GM. A population-based study of skin cancer incidence and prevalence
in renal transplant recipients. Br J Dermatol 2006; 154: 498–504.
9 Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplanta-
tion. N Engl J Med 2003; 348: 1681–1691.
10 Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas
in renal transplant recipients. Br J Dematol 2006; 154: 472–477.
11 Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappel-
man MD. Increased risk for non-melanoma skin cancer in patients
with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8:
268–274.
12 Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T.
Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analy-
sis of population-based cohort studies. Am J Gastroenterol 2010; 105:
1480–1487.
13 Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of non-
melanoma skin cancers among individuals with inflammatory bowel dis-
ease. Gastroenterology 2011; 141: 1612–1620.
14 Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in
inflammatory bowel disease. Cancer 1991; 67: 2015–2019.
15 Peyrin-Biroulet L, Khosrotehrani K, Carrat F et al. Increased risk
for nonmelanoma skin cancers in patients who receive thiopurines
for inflammatory bowel disease. Gastroenterology 2011; 141: 1621–
1628.e1-5.
16 Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and
immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis
2015; 21: 674–698.
17 Ariyaratnam J, Subramanian V. Association between thiopurine use and
nonmelanoma skin cancers in patients with inflammatory bowel disease:
a meta-analysis. Am J Gastroenterol 2014; 109: 163–169.
18 Pasternak B, Svanstrom H, Schmiegelow K, Jess T, Hviid A. Use of
azathioprine and the risk of cancer in inflammatory bowel disease. Am J
Epidemiol 2013; 177: 1296–1305.
19 Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman
MD. Risk of melanoma and nonmelanoma skin cancer among patients
with inflammatory bowel disease. Gastroenterology 2012; 143:
390–399.e1.
20 McKenna MR, Stobaugh DJ, Deepak P. Melanoma and non-mela-
noma skin cancer in inflammatory bowel disease patients following
tumor necrosis factor-a inhibitor monotherapy and in combination
with thiopurines: analysis of the Food and Drug Administration
Adverse Event Reporting System. J Gastrointestin Liver Dis 2014; 23:
267–271.
21 Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or
combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383–
1395.
22 Panaccione R, Ghosh S, Middleton S et al. Combination therapy
with infliximab and azathioprine is superior to monotherapy with
either agent in ulcerative colitis. Gastroenterology 2014; 146: 392–
400.e3.
23 Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J
Gastroenterol Suppl 1989; 170: 2–6; discussion 16-9.
24 O’Brien K, Comber H, Sharp L. Completeness of case ascertainment
at the Irish National Cancer Registry. Ir J Med Sci 2014; 183: 219–
224.
25 Dobson AJ, Barnett AG. An Introduction to Generalized Linear Models,
3rd edn. Chapman & Hall/CRC, Boca Raton, FL; London, 2008.
26 Xiang F, Lucas R, Hales S, Neale R. Incidence of nonmelanoma skin
cancer in relation to ambient UV radiation in white populations,
1978–2012: empirical relationships. JAMA Dermatol 2014; 150:
1063–1071.
27 O’Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA
light generate mutagenic oxidative DNA damage. Science 2005; 309:
1871–1874.
28 International Agency for Research on Cancer. A Review of Human Carci-
nogens, Pharmaceuticals, Volume 100A. Lyon (France): International
Agency for Research on Cancer; 2008.
29 Hakam A, Yeatman TJ, Lu L et al. Expression of insulin-like growth
factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30:
1128–1133.
30 Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I
receptor overexpression mediates cellular radio resistance and local breast
© 2017 European Academy of Dermatology and VenereologyJEADV 2017, 31, 978–985
984 Clowry et al.
cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57:
3079–3083.
31 Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. DNA
repair and aging in basal cell carcinoma: a molecular epidemiology study.
Proc Natl Acad Sci USA 1993; 90: 1614–1618.
32 D’Haens G, Baert F, van Assche G et al. Early combined immunosuppres-
sion or conventional management in patients with newly diagnosed
Crohn’s disease: an open randomised trial. Lancet 2008; 371: 660–667.
33 Vallejo-Torres L, Morris S, Kinge JM, Poirier V, Verne J. Measuring cur-
rent and future cost of skin cancer in England. J Public Health (Oxf) 2014;
36: 140–148.
34 Kerbleski JF, Gottlieb AB. Dermatological complications and safety of
anti-TNF treatments. Gut 2009; 58: 1033–1039.
35 Scott FI, Mamtani R, Brensinger CM et al. Risk of nonmelanoma skin
cancer associated with the use of immunosuppressant and biologic agents
in patients with a history of autoimmune disease and nonmelanoma skin
cancer. JAMA Dermatol 2015; 28: 1–9.
36 Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel
disease treated with azathioprine: a UK population-based case-control
study. Am J Gastroenterol 2010; 105: 1604–1609.
37 Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the
treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50:
485–489.
38 Renna S, Cottone M, Orlando A. Optimization of the treatment with
immunosuppressants and biologics in inflammatory bowel disease.World
J Gastroenterol 2014; 20: 9675–9690.
39 Mowat C, Cole A, Windsor A et al. Guidelines for the management of
inflammatory bowel disease in adults. Gut 2011; 60: 571–607.
40 Algaba A, Guerra I, Marın-Jimenez I et al. Incidence, management, and
course of cancer in patients with inflammatory bowel disease. J Crohns
Colitis 2015; 9: 326–333.
41 Okafor PN, Stallwood CG, Nguyen L et al. Cost-effectiveness of non-
melanoma skin cancer screening in Crohn’s disease patients. Inflamm
Bowel Dis 2013; 19: 2787–2795.
42 Gibson GE, Codd MB, Murphy GM. Skin type distribution and skin dis-
ease in Ireland. Ir J Med Sci 1997; 166: 72–74.
43 Central Statistics Office. Census 2011. Profile 7: Religion, Ethnicity and
Irish Travellers. The Stationary Office, Dublin, 2012.
44 Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R.
Use of thiopurines in the treatment of inflammatory bowel disease is
associated with an increased risk of non-melanoma skin cancer in an
at-risk population: a cohort study. J Gastroenterol Hepatol 2012; 27:
385–389.
45 R Core Team. R: A Language and Environment for Statistical Computing.
R Foundation for Statistical Computing, Vienna, Austria, 2014. Accessed
on 23 February 2015. URL http://www.R-project.org/
46 Venables WN, Ripley BD. Modern Applied Statistics with S, 4th edn.
Springer, UK, 2002.
Appendix 1
A generalized linear model (glm) is a commonly used generaliza-
tion of the standard linear regression model when data are not
assumed to have normally distributed errors. The R function
glm45 fits a logistic regression model to data and produces coeffi-
cient estimates, odds ratios, standard errors and P-values for all
specified explanatory variables.
Using the AIC approach,46 different combinations of explana-
tory variables were used to compare fitted models. The AIC
measures how closely the model fits the data, with a penalty for
model complexity. The ‘best’ model is that deemed to have the
lowest AIC. The P-value selection and AIC approaches (via the
step AIC R function) both agreed on the same model.
A Poisson regression model25 was chosen to reduce errors
accounting for the low incidence of NMSC and small fluctua-
tions in observed cases in age groups of close proximity.
The patient data were recorded in a multiway contingency
table including observed counts of skin cancer (SCC and/or
BCC), age group, gender, azathioprine exposure, anti-TNF
exposure and all immunosuppressant exposure. Age groups were
in 17 categories of 5-year intervals from 0 to 85 years. The
dependent variable for the Poisson regression was observed
counts of skin cancer. Explanatory variables were age group,
gender and immunosuppressant exposure. The natural log (ln)
was used as an offset so that the model reflected the rate of
observed skin cancer relative to patient years. Standard model
diagnostics indicated that the model provided a good fit for the
data.
The relevant incidence rate was applied to the number of
patient years, to provide an ‘expected’ incidence for each row.
The SIR was calculated as the fitted values from the Poisson
regression model divided by these expected values.
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